EMC
53
-3
MPC
47
3
STI
31
19
AVY
53
2
CTSH
65
-3
CVX
38
6
KO
44
2
DUK
50
-2
KEY
46
-2
SWK
56
-6
CF
53
2
LOW
58
2
KSS
42
-3
PCG
99
2
ZTS
49
2
AES
41
2
BLK
70
-2
NRG
50
-2
GLW
48
-5
SWKS
33
-10
EMC
53
-3
MPC
47
3
STI
31
19
AVY
53
2
CTSH
65
-3
CVX
38
6
KO
44
2
DUK
50
-2
KEY
46
-2
SWK
56
-6
CF
53
2
LOW
58
2
KSS
42
-3
PCG
99
2
ZTS
49
2
AES
41
2
BLK
70
-2
NRG
50
-2
GLW
48
-5
SWKS
33
-10
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
32

PTGX
Protagonist Therapeutics

Last Price:
41.02
Seasonality Move:
12.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.

Protagonist Therapeutics Price Quote

$41.02
-1.65 (-3.87%)
(Updated: November 14, 2024 at 5:55 PM ET)

Protagonist Therapeutics Key Stats

Sell
32
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$42.39 - $43.85
52-week range:
$15.58 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.24
P/B ratio:
4.84%
Volume:
594.2K
Avg. volume:
507.4K
1-year change:
170.23%
Market cap:
$2.6B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 54.38
Upside from Last Price: 27.43%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    105.4M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders